Compare CTXR & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTXR | AMS |
|---|---|---|
| Founded | 2007 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 14.2M |
| IPO Year | N/A | N/A |
| Metric | CTXR | AMS |
|---|---|---|
| Price | $0.83 | $2.13 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 338.1K | 7.3K |
| Earning Date | 02-13-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $29,423,000.00 |
| Revenue This Year | N/A | $3.81 |
| Revenue Next Year | $147.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 17.84 |
| 52 Week Low | $0.63 | $2.01 |
| 52 Week High | $3.35 | $3.21 |
| Indicator | CTXR | AMS |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 42.35 |
| Support Level | $0.79 | $2.08 |
| Resistance Level | $0.85 | $2.15 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 34.76 | 11.19 |
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.